Abstract
Schwann cells, the myelin forming cells in the peripheral nervous system, play a key role in the pathology of various inflammatory, metabolic and hereditary polyneuropathies. Advances in identifying growth factors and signaling molecules that are expressed by Schwann cells have paved the way for development of new treatment strategies that are aimed to improve the protective and regenerative properties of Schwann cells in peripheral nerve disorders. These include the exogenous application of growth factors and neurohormones which have been advanced into clinical trials in humans, and transplantation paradigms that have been moved into late stage preclinical models. In this review we will discuss the latest developments in these therapeutic approaches with special regard to peripheral nerve disorders, in which progress in basic research has already been translated into clinical trials, including HIV-associated distal sensory polyneuropathy and diabetic neuropathy.
Keywords: Schwann cells, myelination, regeneration, nerve injury, peripheral nerve, polyneuropathy, diabetic neuropathy, HIV-SN, HIV-Associated Distal Sensory Polyneuropathy, antiretroviral toxic neuropathy, NRTIs, Charcot-Marie-Tooth Disease, CMT1A, HNPP, pmp22, microangiopathy, polyol pathway, Neurotrophins, Gracely Pain Scale, temporal hyperalgesia, Eyrthropoetin, rhEPO, Progesterone, Ascorbic Acid
CNS & Neurological Disorders - Drug Targets
Title: Schwann Cells as a Therapeutic Target for Peripheral Neuropathies
Volume: 9 Issue: 6
Author(s): Helmar C. Lehmann and Ahmet Hoke
Affiliation:
Keywords: Schwann cells, myelination, regeneration, nerve injury, peripheral nerve, polyneuropathy, diabetic neuropathy, HIV-SN, HIV-Associated Distal Sensory Polyneuropathy, antiretroviral toxic neuropathy, NRTIs, Charcot-Marie-Tooth Disease, CMT1A, HNPP, pmp22, microangiopathy, polyol pathway, Neurotrophins, Gracely Pain Scale, temporal hyperalgesia, Eyrthropoetin, rhEPO, Progesterone, Ascorbic Acid
Abstract: Schwann cells, the myelin forming cells in the peripheral nervous system, play a key role in the pathology of various inflammatory, metabolic and hereditary polyneuropathies. Advances in identifying growth factors and signaling molecules that are expressed by Schwann cells have paved the way for development of new treatment strategies that are aimed to improve the protective and regenerative properties of Schwann cells in peripheral nerve disorders. These include the exogenous application of growth factors and neurohormones which have been advanced into clinical trials in humans, and transplantation paradigms that have been moved into late stage preclinical models. In this review we will discuss the latest developments in these therapeutic approaches with special regard to peripheral nerve disorders, in which progress in basic research has already been translated into clinical trials, including HIV-associated distal sensory polyneuropathy and diabetic neuropathy.
Export Options
About this article
Cite this article as:
C. Lehmann Helmar and Hoke Ahmet, Schwann Cells as a Therapeutic Target for Peripheral Neuropathies, CNS & Neurological Disorders - Drug Targets 2010; 9 (6) . https://dx.doi.org/10.2174/187152710793237412
DOI https://dx.doi.org/10.2174/187152710793237412 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Phosphorylation-Dephosphorylation Imbalance of Cytoskeletal Associated Proteins in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies
Current Diabetes Reviews Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Thalidomide as an Immunotherapeutic Agent: The Effects on Neutrophil- Mediated Inflammation
Current Pharmaceutical Design Metabotropic Glutamate Receptors as Targets for Analgesia: Antagonism, Activation, and Allosteric Modulation
Current Pharmaceutical Biotechnology Chymase Inhibitors
Current Pharmaceutical Design Aspects of the Stability and Bioavailability of Carbohydrates and Carbohydrate Derivatives
Mini-Reviews in Medicinal Chemistry Mitochondrial Dysfunction in Huntington’s Disease: Pathogenesis and Therapeutic Opportunities
Current Drug Targets Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Mechanisms and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Dysglycemia and Abdominal Obesity
Current Vascular Pharmacology Nutraceuticals and Diet-based Phytochemicals in Type 2 Diabetes Mellitus: From Whole Food to Components with Defined Roles and Mechanisms
Current Diabetes Reviews Estimation of Abbreviated Mycophenolic Acid Area Under the Concentration- Time Curve during Stable Post-transplant Period by Limited Sampling Strategy
Current Reviews in Clinical and Experimental Pharmacology The Many Facets of Cell Injury: Angiogenesis to Autophagy
Current Neurovascular Research Taurine-Diabetes Interaction: From Involvement to Protection
Current Diabetes Reviews Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Molecular Mechanism of Aggravation of Hypertensive Organ Damages by Short-Term Blood Pressure Variability
Current Hypertension Reviews